



Please find our Research on Bloomberg BRYG <GO>)

18th August 2016

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18552.02	-0.45%	+6.47%
S&P 500	2178.15	-0.55%	+6.57%
Nasdaq	5227.11	-0.66%	+4.39%
Nikkei	16486.01	-1.55%	-12.80%
Stoxx 600	343.318	-0.79%	-6.15%
CAC 40	4460.44	-0.83%	-3.81%
Oil /Gold			
Crude WTI	45.74	0.00	+22.96%
Gold (once)	1348.07	+0.45%	+26.89%
Currencies/Rates			
EUR/USD	1.126	+0.56%	+3.65%
EUR/CHF	1.08495	-0.32%	-0.23%
German 10 years	-0.089	-30.51%	-114.08%
French 10 years	0.19	+25.27%	-80.63%
Euribor	-	+-%	+-%

Economic releases :

Date 18th-Aug

GBP - Retail Sales Jul. (3.9% YOY E) EUR - Euro-Zone Consumer Price Index (0.1% YOY E) USD - Initial Jobless Claims Aug. (265k E)

USD - Continuing Claims Aug. (2,141k E)

Upcoming BG events : Date 1st-Sept L'OREAL (BG Paris roadshow with CFO) 8th-Sept ACCOR (BG Roadshow with CFO) 13th-Sept Thematic Breakfast with ARCEP 14th-Sept SAINT GOBAIN (BG Luxembourg roadshow) 22nd-Sept Thematic Lunch with HC specialist 30th-Sept Thematic Breakfast with Vimpelcom

Recent reports :

26th-Jul	NICOX Don't turn a blind eye to opportunities
21st-Jul	SEMICONDUCTORS : Looking for lost growth
13th-Jul	Oncology is an increased focus
12th-Jul	DANONE No redemption
1st-Jul	UBISOFT Same player shoot again?
29th-Jun	ORANGE : Lights are turning green.

List of our Reco & Fair Value : Please click here to download



BG's Wake Up Call

BUY, Fair Value CHF80 (+1%)

Pricing slowing down

NESTLÉ

This morning, Nestlé reported Q2 sales in line with consensus in reported and slightly below in organic. Sales amounted to CHF22,221m (consensus: CHF22,294m and our estimate: CHF22,059m), up 1.4% in reported and 3.1% in organic. The EBIT margin increased 30bps both in reported and in constant currencies to 15.3% (consensus and our estimate: 15.2%), reflecting a tailwind coming from input costs. The group confirmed its full year outlook and said that pricing should recover in the coming months from the historically low level in H1. It seemed to be confident, excluding for China which was reported to have slowed down in Q2.

CONSTRUCTION & MATERIALS

Q2 earning seasons review - Where is my upside gone?

Earning season for the sector has been positive, so far, for our coverage. Companies appeared to be properly managed, with usually improved profitability. Difficulties have not disappeared though, like macro uncertainties in Europe, a deflationist environment and sometimes poor volumes – but companies can deal with them. While French Contractors remain safe harbour, cement majors might benefit from a better momentum from some Emerging Markets. Saint-Gobain offers the most upside.

ENVIRONMENTAL SERVICES

Q2 earning season review: toward strategies' convergence...again

As expected, both Suez and Veolia are still bearing the brunt of a challenging macro environment which has negatively impacted their traditional water and waste businesses in H1-16. We however still appreciate the resilience of the company's margins whose main driver remains companies' abilities to deliver their respective cost-savings programme. We believe these savings combined with strong international developments will be the two pillars of a new strategies' convergence between both companies. We maintain our Buy rating on both stocks while leaving our FV unchanged (EUR17.5 for Suez and EUR23.5 for Veolia).

Food & Beverages

Price CHF78.95

Bloomberg Reuters 12-month High / L Market Cap (CHF) Ev (BG Estimates) Avg. 6m daily volu 3y EPS CAGR		N 79.	NESN VX ESZn.VX 9 / 68.4 245,705 256,575 5 579 7.0%	
	1 M	3 M	6 M 31	/12/15
Absolute perf.	1.4%	8.2%	8.1%	5.9%
Food & Bev.	0.4%	4.4%	7.0%	0.8%
DJ Stoxx 600	1.6%	2.6%	7.2%	-6.1%
YEnd Dec. (CHFm)	2015	2016e	2017e	2018e
Sales	88,785	89 <i>,</i> 899	93,836	99,476
% change		1.3%	4.4%	6.0%
EBITDA	17,210	17,958	19,023	20,316
EBIT	13,382	13,968	14,902	16,083
% change		4.4%	6.7%	7.9%
Net income	10,351	10,901	11,701	12,631
% change		5.3%	7.3%	7.9%
	2015	2016e	2017e	2018e
Operating margin	15.1	15.5	15.9	16.2
Net margin	11.7	12.1	12.5	12.7
ROE	16.6	16.7	17.5	18.0
ROCE	12.5	12.9	14.1	15.4
Gearing	0.9	0.6	0.4	0.1
(CHF)	2015	2016e	2017e	2018e
EPS	3.30	3.49	3.75	4.05
% change	-	5.9%	7.3%	7.9%
P/E	23.9x	22.6x	21.1x	19.5x
FCF yield (%)	4.0%	4.2%	4.5%	4.8%
Dividends (CHF)	2.25	2.30	2.35	3.35
Div yield (%)	2.8%	2.9%	3.0%	4.2%
EV/Sales	2.9x	2.9x	2.7x	2.5x
EV/EBITDA	15.2x	14.3x	13.3x	12.2x
EV/EBIT	19.5x	18.4x	17.0x	15.4x



Pricing slowing down

Fair Value CHF80 (+1%)

This morning, Nestlé reported Q2 sales in line with consensus in reported and slightly below in organic. Sales amounted to CHF22,221m (consensus: CHF22,294m and our estimate: CHF22,059m), up 1.4% in reported and 3.1% in organic. The EBIT margin increased 30bps both in reported and in constant currencies to 15.3% (consensus and our estimate: 15.2%), reflecting a tailwind coming from input costs. The group confirmed its full year outlook and said that pricing should recover in the coming months from the historically low level in H1. It seemed to be confident, excluding for China which was reported to have slowed down in Q2.

ANALYSIS

- **Pricing growth decelerating.** In Q2 sales were up 1.4% to CHF22,221m (consensus: CHF22,294m and our estimate: CHF22,059m). In organic, they rose 3.1% (consensus: +3.6% and our estimate: +3.7%), below the Q1 trend (+3.9%) and mainly driven by volumes/mix (+2.6% in Q2). The pricing continued to slow down, only up 0.7% after +0.9% in Q1. This is contrary to Nestlé's comments at the release of the Q1 sales but is not surprising given the deflationary environment in a number of markets, the tough comparison base (price increases in Latam and Eastern Europe) and the lack of rebound in commodity prices.
- EBIT margin up 30bps. The H1 EBIT came out in line with market expectations. It increased 2.6% to CHF6,603m (consensus: CHF6,554m and our estimate: CHF6,548m), implying a margin of 15.3%, (consensus and our estimate: 15.2%), up 30bps both in reported and in constant currencies thanks to a tailwind coming from input costs. Underlying EPS rose 5.8% in reported and 5.7% ex-FX to CHF1.65.
- No change in trend in Americas despite negative technical effects. This division (29% of group's sales) posted 5.2% organic sales growth in Q2 (after +5% in Q1) driven by frozen meals, Coffee-mate and petcare. Latin America was resilient despite the poor macro background and the low dairy prices in Brazil.
- Q2 organic sales in Europe/Middle East/North Africa (18% of group's sales) slowed down. Q2 sales increased 2.0% organically, impacted by the pressure from retailers in Europe, the low commodity prices (coffee and dairy) and the political instability in countries of the Middle East.
- China still weighing on Asia/Oceania/Sub-Saharan Africa (17% of group's sales). Q2 organic sales were up 2.5% after +2.1% in Q1. The group reported a significant slowdown in the food and beverage market in China and said it remained focused in improving its Yinlu business. The comparison base remains difficult in India as Maggi noodles were recalled in mid Q2.
- In the other divisions. Sales of Nestlé Nutrition (13% of groups's sales) were flat in Q2 due to China and the US. Waters (9% of group's sales) continued to be solid, with organic sales up 3.3%. Finally, sales of Other Businesses (16% of group's sales) rose 3.3% driven by double digit growth at Nestlé Health Science.
- 2016 guidance confirmed. The group aims to achieve organic sales growth in 2016 in line with 2015, that-is-to-say +4.2%, with improvement in margin and underlying earnings per share in constant currencies. The company also indicated that pricing should recover somewhat in the coming months.

VALUATION

• We maintain our estimates before the conference call at 8h30 am CEST. Our DCF currently points to a Fair Value of CHF80.

NEXT CATALYSTS

Q3 2016 sales in October: Unilever on 13th, Danone on 18th and Nestlé on 20th

Click here to download



Analyst : Virginie Roumage 33(0) 1.56.68.75.22 vroumage@bryangarnier.com Sector Team : Nikolaas Faes Loïc Morvan Antoine Parison Cédric Rossi

Return to front page

BUY


Return to front page

Sector View

Construction & Materials

	1 M	3 M	6 M	31/12/15
Cons & Mat	6.9%	6.4%	16.5%	4.5%
DJ Stoxx 600	1.6%	2.6%	7.2%	-6.1%
*Stoxx Sector Indices				

Companies cov	ered		
CRH		BUY	EUR30
Last Price	EUR29.06	Market Cap.	EUR24,112m
EIFFAGE		BUY	EUR73
Last Price	EUR69.89	Market Cap.	EUR6,855m
HEIDELBERGCE	MENT	BUY	EUR86
Last Price	EUR81.14	Market Cap.	EUR16,099m
IMERYS		BUY	EUR72
Last Price	EUR64.05	Market Cap.	EUR5,097m
LAFARGEHOLCI	М	BUY	CHF50
Last Price	CHF51.4	Market Cap.	CHF31,195m
SAINT GOBAIN		BUY	EUR46
Last Price	EUR39.035	Market Cap.	EUR21,661m
VICAT		NEUTRAL	EUR56
Last Price	EUR57	Market Cap.	EUR2,559m
VINCI		BUY	EUR72
Last Price	EUR67.6	Market Cap.	EUR40,262m



Q2 earning seasons review - Where is my upside gone?

Earning season for the sector has been positive, so far, for our coverage. Companies appeared to be properly managed, with usually improved profitability. Difficulties have not disappeared though, like macro uncertainties in Europe, a deflationist environment and sometimes poor volumes – but companies can deal with them. While French Contractors remain safe harbour, cement majors might benefit from a better momentum from some Emerging Markets. Saint-Gobain offers the most upside.

ANALYSIS

- French contractors remain a specific type of investment within the sector, with a significant exposure to toll roads (two thirds of EBIT) and infrastructures (half of sales or more). Toll roads traffic at end June is strong (+3.3% for Vinci Autoroutes, +4.1% for APRR) and Vinci has recently lift its FY guidance to 2.5% (vs less than 2% implicit previously). Even with limited price effect (less than 1.5% efor cars on 1st February 2016), EBITDA margin are likely to continue to improve. On the Contracting side, Vinci said to stand now at the trough of the cycle for French roadworks, while it might appear relatively soon for the other segments. On the valuation side, upsides are more limited but Vinci newsflow is likely to be filled with new M&A in energy and new concession projects. All in all, French Contractors remain safe harbours in difficult times.
- Unlike most of the cement players, CRH has not reported interim figures yet but has already indicated H1 2016 EBITDA should be close to cEUR1.1bn vs EUR1bn previously guided, presumably benefited from its unique exposure to North America (c60% of the EBITDA PF). Recent rumours regarding the possible inclusion of CRH into the EuroStoxx50 index has helped too. Hence share price has been strong this year (+9%), significantly reducing the upside. The three other cement players under coverage have all reported good Q2 figures, with usually significant EBITDA margin improvement. Comments on the US markets are usually positive (cement shipments up 7.3% at end June, housing starts up 5.6% y/y at end July), with good momentum for prices. In LatAm, situation is more contrasted, with some positive trends in Mexico and some prices increase in Colombia or Argentina but of course situation is complicated for Brazil. Africa-Middle East region trends are mixed, with some difficulties in Nigeria (currency, security), illustrated by very poor figure for Dangote Cement in Q2 2016 (EBITDA margin at 40% vs 59% in Q2 2015) but better trends in some country like Egypt or Algeria. Finally, in Asia, India market continue to recover with good volumes in H1 for Vicat (+28%) but more subdued for LHN (+1.5%) due to pricing policy, and overall decent outlook. Indonesia looks more complicated with volumes increase but not everywhere (not within the Heidelberg footprint for instance). It worth underlying Italcementi H1 2016 EBITDA performance was poor, down 7.6% at EUR300m, which is a negative read-across for HEI. It worth underlying however than HEI has announced this morning the disposal of the Martinsburg Cement Plant in the US, in order to comply with anti-trust demands and its EUR1bn disposal target has been now exceeded.
- Both Saint-Gobain and Imerys have reported well-oriented Q2 results, although Imerys is still penalised by very modest volumes trends (-3.3% in Q2). We have been reassured by comments of SGO regarding the new-built activity in France, which "showed the first signs of improvement" (Nexity has reported reservations up +38% in H1 2016, housing starts are up 5% rolling-12 months at end June), but the share price reaction has been limited (1.7% on 29 July), probably penalised by unchanged comments for the French renovation and a disappointing publication for the French GDP in Q2 (0%) on the same day. France represents a quarter of SGO sales. SGO and NK are the two stocks for which we still got some decent upside.

Revenues organic growth and operating margin in the first two quarters
--

y/y	HEI	NK	LHN	SGO	VCT	DG
Q1 sales organic growth (%)	1.0%	-1.8%	0.1%	1.8%	6.5%	-3.3%
Q2 sales organic growth (%)	1.0%	-2.6%	-2.1%	3.8%	2.5%	-1.9%
Q1 EBITDA/EBIT margin (bps)*	70	30	-280	nc	nc	nc
Q2 EBITDA/EBIT margin (bps)*	140	100	210	nc	nc	nc
H1 EBITDA/EBIT margin (bps)*	110	70	-10	60	50	120

Source : Company Data; Bryan Garnier & Co. ests.

NEXT CATALYSTS

CRH to report interim results on 25 August and Eiffage on 31th August.

Click here to download

Analyst :



Eric Lemarié 33(0) 1.70.36.57.17 elemarie@bryangarnier.com

Sector View

Environmental Services

	1 M	3 M	6 M	31/12/15
Utilities	-2.7%	0.4%	4.3%	-4.5%
DJ Stoxx 600	1.6%	2.6%	7.2%	-6.1%
*Stoxx Sector Indices				

Companies covered

AMOEBA				
Last Price	EUR29,6	Market Cap.	EUR177m	
PENNON GROU	JP	SELL	830p	
Last Price	890,5p	Market Cap.	GBP3,676m	
SUEZ		BUY	EUR17,5	
Last Price	EUR13,945	Market Cap.	EUR7,592m	
VEOLIA ENVIRO	ONNEMENT	BUY	EUR23,5	
Last Price	EUR19,685	Market Cap.	EUR11,090m	



Q2 earning season review: toward strategies' convergence...again

As expected, both Suez and Veolia are still bearing the brunt of a challenging macro environment which has negatively impacted their traditional water and waste businesses in H1-16. We however still appreciate the resilience of the company's margins whose main driver remains companies' abilities to deliver their respective cost-savings programme. We believe these savings combined with strong international developments will be the two pillars of a new strategies' convergence between both companies. We maintain our Buy rating on both stocks while leaving our FV unchanged (EUR17.5 for Suez and EUR23.5 for Veolia).

ANALYSIS

- Cost-savings as main growth driver: as expected, cost-savings remain the main driver for both companies' EBITDA growth. We have been quite impressed by Veolia's performance over the first half of the year as the company reached EUR121m of costs-savings, ahead of its annual objective (EUR200m per year in 2016, 2017 and 2018). As for Suez, we appreciate the additional EUR30m cost-savings announced by the company which increases the company's annual objective upgrade to EUR180m for 2016 (still EUR150m for 2017). Suez also announced it aims to speed up its transformation plan whose details should be unveiled during Q3 2016 results, which could create a positive momentum on the stock. We understand from management that mobility and formation actions could be envisaged without any additional details disclosed for now.
- Strong international developments: Both companies are on their way to offset the rather challenging macro environment in their traditional European water (low inflation) and waste (still flattish industrial production) businesses by strong international developments. We bet on a stronger growth for Veolia in H2-16 and in 2017 as the company will benefit from new international revenues' sources from a mix of bolt-on acquisitions (Chemours assets, Kurion) and contracts (industrial water with Sinopec) which should represent c. 2.0% of the company's 2017e revenues. Suez still expects to annually grow by 6% to 8% in its international businesses between 2016 and 2018. The company posted a 11.6% organic growth in the division in H1-16, which led us to revise upward our estimates (+9.7% and +7.5% organically in 2016 and 2017 in the division vs. + 6.7% and +6.8% before) in our previous note.
- Conclusion: As Suez put aside its 2017 EBITDA ambition which were based on M&A we believe both companies' strategies will now converge again through self-help measures and strong international developments. Additionally, we remain confident over the ability of both companies to reach their respective guidance for 2016: (EUR600m of adjusted net income for Veolia; revenues' organic growth higher than 2% and EBIT's organic growth higher than revenues' growth for Suez). We maintain therefore our Buy rating on Suez (FV @ EUR17.5) and Veolia (FV @ EUR23.5). Veolia remains our Top Pick within the sector for Q3-16.

VALUATION

- At current share price, Suez and Veolia are respectively trading at 7.0x and 6.6x 2016e EV/EBITDA.
- Suez: Buy, FV @ EUR17.5
- Veolia: Buy, FV @ EUR23.5 Top Picks

NEXT CATALYSTS

- 27th October: Suez's Q3 2016 results
- **3rd November:** Veolia's Q3 2016 results

Click here to download

Analyst :	Sector Team :
Pierre-Antoine Chazal	Xavier Caroen
33(0) 1.56.68.75.06	
pachazal@bryangarnier.com	

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a
	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to
	be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary
	event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key
	reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.7%

NEUTRAL ratings 33.6%

SELL ratings 10.7%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud (Head of Equities)	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
ТМТ	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut (Head of Research)	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager Eric Monnier 33(0) 1 56 68 75 63 emonnier@bryangarnier.com				

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	Fax +91 11 2621 9062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Geneva
Authorised and regulated by the				rue de Grenus 7 CP 2113
Financial Conduct Authority (FCA) the Autorité de Contrôle prudential et			Genève 1, CH 1211
	de resolution (ACPR)			Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA



BRYAN, GARNIER & CO

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB, United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris, France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited inducted and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....